5 results
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
The aim of this study is to evaluate whether a 30-minute episode of helium breathing in humans affects the ability of the immune system to respond to ex vivo stimulation in whole blood taken from healthy volunteers.
The aim of this clinical study is to investigate whether the non-anaesthetic noble gas helium induces EPC and LPC of human endothelium in vivo.
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease